statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

T2 Biosystems, Inc. (NASDAQ:TTOO - Get Free Report) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $13.76 and...

T2 Biosystems (NASDAQ:TTOO) Stock Crosses Below 200-Day Moving Average of $13.76

T2 Biosystems (TTOO) has shared an announcement. The Company has announced the extension of its capital equipment supplier agreement with Vizient...

T2 Biosystems Reinforces Market Position with Extended Vizient Agreement

T2 Biosystems extends contract with Vizient...

T2 Biosystems extends contract with Vizient

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

T2 Biosystems announces extension of multi-year agreement with Vizient

LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

T2 Biosystems unveils T2Lyme launch plans, business updates

Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the Company ), a leader in the...

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the Company ), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes...

T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates

Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genesLEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2...

T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel

LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Volume	32,253.00
52-Wk High	$70.00
52-Wk Low	$2.60

TTOO T2 Biosystems Inc

About

Feed

News

Sentiment

Earnings

Fundamentals